You are here: Industry Insights > Genentech

News List

Genentech announces results of IMspire150 study in BRAF V600 mutation-positive advanced melanoma pharmaceutical-business-review
December 20, 2019
Genentech, a member of the Roche Group, announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma ...
Mimetas Chairman of the Board Herbert Heyneker Receives Dutch Royal Honor b3cnewswire
September 23, 2019
Herbert ‘Herb’ Heyneker, Chairman of the Board of Directors at Mimetas and Dutch biotech pioneer, has been honored by the Dutch Monarchy for his contributions ...
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) biospectrumasia
September 18, 2019
Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies.
Enable Injections, Genentech Enter Partnership contractpharma
August 22, 2019
enFuse technology allows patients to self-administer subcutaneous treatments outside of clinical setting.
Genentech gets FDA approval for tumour-agnostic drug Rozlytrek pharmaceutical-technology
August 19, 2019
The US Food and Drug Administration (FDA) has approved Roche division Genentech’s tumour-agnostic drug Rozlytrek, which targets a specific genetic defect called neurotrophic tyrosine receptor kinase (NTRK).
Sosei Heptares and Genentech enter GPCR target alliance pharmaceutical-technology
July 18, 2019
Japanese biopharmaceutical group Sosei Heptares has partnered with Roche subsidiary Genentech for the discovery and development of drugs that modulate G protein-coupled receptor (GPCR) targets.
Convelo, Genentech to Collaborate on Remyelinating Therapies contractpharma
July 18, 2019
Aims to treat patients with neurological disorders such as multiple sclerosis.
Sosei Heptares teams up with Genentech for multi-target R&D biospectrumasia
July 17, 2019
Collaboration aims to discover and develop novel medicines that modulate G protein-coupled receptor (GPCR) targets across a range of diseases
Sosei Heptares, Genentech Announces Research, License Agreement americanpharmaceuticalreview
July 17, 2019
Sosei Group has entered into a multi-target research collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop novel medicines (new small molecules and/or biologics) that modulate G protein-coupled receptor (
Skyhawk, Genentech Enter Exclusive Multi-target RNA Alliance contractpharma
July 17, 2019
Will leverage SkySTAR platform to discover and develop small molecule treatments for oncology and neurological disease targets.

Previous page 1 2 3 4 5 6 7 8 Next page